Dual-target ADC

This invention

This invention is a dual-targeting antibody-drug conjugate (ADC) for cancer immunotherapy. It brings two targets together in one molecule: PD-L1, an immune checkpoint that tumors use to hide from T-cells, and VEGFR-2, a receptor that drives the blood-vessel growth tumors depend on. A cleavable linker carries a microtubule-disrupting payload that, once released inside the targeted cell, stops cell division. The work sits in biologic cancer therapeutics, at the meeting point of immuno-oncology, anti-angiogenesis, and targeted drug delivery.

Where it fits

Your idea lives in a well-developed corner of biologic therapeutics. The central area is Peptides & Proteins (C07K), which appears in all 50 of these 50 results and is about 53× more concentrated here than in the patent corpus overall. Close by are Pharmaceutical Preparations (A61K) and Therapeutic Drug Activity (A61P). That tight clustering is a healthy sign — it marks a real, actively pursued direction. Filings climbed from 2017 to 2021, peaking at 7–8 per year in 2017–2018, with fresh activity continuing into 2024–2025. Several groups have been working nearby, including Medarex, MSD OSS, Ono Pharmaceutical, Emory University, Seattle Genetics, and the Board of Regents of the University of Texas System. The space also reaches into Heterocyclic Compounds (C07D), the small-molecule chemistry these results touch less often.

Closest related work

US-11780922-B2 — Bifunctional proteins combining checkpoint blockade for targeted therapy (AP Biosciences Inc · 0 citations · 24-member family, filed 2023, recent)

This patent describes bispecific proteins that pair a cell-surface binding domain with a VEGF-inhibiting domain. It explicitly extends to an antibody-drug conjugate carrying a therapeutic agent conjugated to an antibody binding PD-L1 and/or a VEGF-inhibiting domain. It shows how AP Biosciences approached the same combination you're exploring — checkpoint blockade, anti-angiogenesis, and a conjugated payload in a single construct. That makes it a close conceptual neighbor and a useful reference for the dual-target-plus-payload architecture.

US-12325759-B2 — Anti-VEGF-anti-PD-L1 bispecific antibody, pharmaceutical composition of same, and uses thereof (Biotheus Inc · 0 citations · 12-member family, filed 2025, recent)

This very recent filing centers on a bispecific antibody with one functional region targeting VEGF and another targeting PD-L1. It shows how Biotheus structured a dual VEGF/PD-L1 binding molecule and its pharmaceutical formulations. It focuses on the bispecific antibody rather than an ADC payload, but it tackles the same two targets you're combining — a valuable look at the antibody-engineering side of your concept.

US-7829531-B2 — Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease (Seattle Genetics Inc · 183 citations · 54-member family)

This foundational ADC patent describes drug-linker-ligand conjugates in which a drug connects to an antibody through a peptide-based, cleavable linker. It shows how Seattle Genetics approached the core ADC chemistry — linker design and payload attachment — that underpins your cleavable-linker, microtubule-disruptor approach. It's a widely cited reference for the conjugation mechanics, independent of which antigen the antibody targets.

US-6342219-B1 — Antibody compositions for selectively inhibiting VEGF (Board of Regents The University of Texas System · 644 citations · 38-member family)

This patent covers antibodies that selectively block VEGF from binding VEGFR-2, inhibiting angiogenesis and inducing tumor regression with improved safety. It shows how this group approached the VEGFR-2 arm of your idea — selective receptor targeting to shut down tumor blood-vessel growth. It's a strong reference for the anti-angiogenesis half of your dual-targeting concept.

What you can do next

• Explore & build on it. Browse the related work above. New, differentiated ideas often come from combining or improving on existing approaches